A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with serplulimab as first-line treatment in patients with extensive-stage small cell lung cancer.

Trial Details

NCT ID
NCT07739758
Phase
PHASE3
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • YL201
  • Serplulimab
  • Carboplatin
  • Etoposide
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Voluntarily sign the written informed consent form and comply with the protocol requirements
  • Age ≥18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →